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MILD TRAUMATIC BRAIN INJURY IN CONTACT SPORT ATHLETES AND 
THE DEVELOPMENT OF NEURODEGENERATIVE DISEASE  
 
NICHOLAS CALITRI  
ABSTRACT 
  
Every year an estimated 42 million people worldwide suffer a mild traumatic 
brain injury (MTBI) or concussion, with approximately 3.6 million sports related 
concussions occurring yearly in the United States alone (Bailes, 2015, Azad et al., 2015).  
An MTBI is an acute brain injury resulting from mechanical energy to the head from 
external forces (Bailes 2015).  Symptoms of an MTBI include visual disturbances, 
dizziness, nausea and vomiting, light sensitivity, loss of balance, and a general feeling of 
fatigue (Bailes 2015).  MTBI’s are first diagnosed through changes in ImPACT baseline 
scores as well as Vestibular Ocular Motor Screening (Mucha et al., 2014).  Repetitive 
MTBI and/or repetitive sub-concussive head trauma have been tentatively linked to 
increased risk for a variety of neurodegenerative diseases including chronic traumatic 
encephalopathy (CTE) (Gardner et al., 2015).  The major limitation of the link between 
MTBI and CTE is that CTE can only be diagnosed post-mortem (Azad et al., 2015). Due 
to that limitation, the prevalence of CTE is unknown and the amount of MTBI or sub-
concussive trauma exposure necessary to produce CTE is unclear (Gardner et al., 2015).  
Newer methods of research including SNTF immunostaining and L-COSY are being 
further developed and studied to better diagnose MTBI and its link to CTE by exploring 
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changes in brain protein formation and brain neurochemistry (Johnson et al., 2015, Lin et 
al., 2015).  Through research development and case studies on professional American 
football players and boxers, a link between MTBI, particularly repetitive MTBI and CTE 
has been formed (Maroon et al., 2014).    
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A large number of epidemiological evidence exists that moderate or severe 
traumatic brain injury (TBI) is a major risk for development of neurodegenerative 
diseases including Alzheimer’s disease and Parkinson’s disease (Gardner et al., 2015).  
What is limited in research, but has recently gained resurgence due to the highly 
publicized testimonies of professional American football players and boxers is the link 
between mild traumatic brain injury (MTBI), or concussions, and neurodegenerative 
diseases, specifically chronic traumatic encephalopathy (CTE) (Gardner et al., 2015).  
The media spotlight on MTBI has led to a number of recent studies to improve research 
on the development of concussions and its link to neurodegenerative diseases (Bailes, 
2015).  Some of the most important studies have been case studies on deceased American 
football players, specifically their change in behavior during the latter portion of their 
lives and the change in their brain neurochemistry (Maroon et al., 2014).  Through the 
new discoveries in research many questions have yet to be answered including what is the 
prevalence of CTE amongst contact sport athletes and how many MTBI’s are necessary 
to develop CTE (Gardner et al., 2015). This thesis will summarize MTBI, the symptoms 
that often present, how to diagnose a concussion, and the long-term effects of repetitive 
MTBI.  This thesis will review recent developments in prevention and treatments in 
MTBI, which are aimed to decrease the percentage of developing CTE.  It will also 
attempt to link MTBI with the formation of CTE through multiple case studies of contact 
sport athletes and will also point out which athletes are most at risk to MTBI and CTE.  
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What is an MTBI? 	   According to the World Health Organization and Centers for Disease Control and 
Prevention (CDC) MTBI is defined as “an acute brain injury resulting from mechanical 
energy to the head from external physical forces. Operational criteria for clinical 
identification include: (1) one or more of the following: confusion or disorientation, loss 
of consciousness for 30 min or less, post-traumatic amnesia for less than 24 h, and/or 
other transient neurological abnormalities such as focal signs, seizure, and intracranial 
lesion not requiring surgery; (2) Glasgow Coma Scale score of 13–15 after 30 min post-
injury or later upon presentation for healthcare and (3) These manifestations of MTBI 
must not be due to drugs, alcohol, medications, caused by other injuries or treatment for 
other injuries (e.g., systemic injuries, facial injuries or intubation), caused by other 
problems (e.g., psychological trauma, language barrier or coexisting medical conditions) 
or caused by penetrating craniocerebral injury” (Collins et al., 2004).  MTBI is better 
known by the idiom concussion, stemming from the Latin word ‘concutere’, which 
means to shake violently (Bailes, 2015, Maroon et al., 2014).  Most often, MTBI are 
caused by a blow or jolt to either the head or the body that causes the brain to move 
rapidly inside the skull and often causes impairment of neurological function (Bailes, 
2015, Maroon et al., 2014).  The acute phase of MTBI is characterized by a 10% risk for 
intracranial irregularities including contusion, subdural or epidural hematoma, brain 
swelling, subarachnoid hemorrhage, or pneumocephalus (Vos et al., 2011).   
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The guideline based on the Glasgow Coma Scale (GCS) allows risk factors to be 
defined and initiated a set of rules for diagnostic CT scan imaging, observation, and 
follow up on patients (Vos et al., 2011).  As seen in Table 1, the lower the GCS score, the 
more critical the head trauma is and the greater the immediate need for a head CT scan is 
(Vos et al., 2011).  MTBI range from category 1, which is less severe, to category 3, 
which is more severe and requires the immediate need for a CT scan of the head (Vos et 
al., 2011).   
 MTBI are extremely prevalent (Azad et al., 2015).  Every year an estimated 42 
million people worldwide suffer a mild traumatic brain injury (MTBI) or concussion, 
with approximately 3.6 million sports related concussions occurring yearly in the United 
States alone (Bailes, 2015, Azad et al., 2015).  It is estimated that between 100 and 300 
people per every 10,000 are medically treated for MTBI annually worldwide, but the true 
number of MTBI per 10,000 people likely doubles because many people do not seek out 
medical attention (Gardner et al., 2015).  Most cases of MTBI are due to falls or motor 
vehicle accidents, but specific sub-populations like contact sport athletes seem to be at an 
elevated risk for suffering MTBI and repetitive MTBI (Gardner et al., 2015).  Research is 
limited in the effects of repetitive MTBI, but it is known that prior TBI is a risk factor for 






Table 1 Classification of traumatic brain injury and indication for immediate head CT 
 
(Vos et al., 2011) 
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Current Facts of MTBI 
 MTBI, or concussions, are one of the most recognized sports related injuries in 
today’s society.  An estimated 3.6 million sports related concussions occur yearly in the 
United States alone, while close to 42 million people annually suffer MTBI from a 
variety of ways (Bailes, 2015, Azad et al., 2015).  10% of all contact sport athletes suffer 
a concussion yearly, 87% of professional boxers have sustained a concussion, and 5% of 
soccer players have sustained a concussion (Bailes, 2015).  When narrowing it down to 
American high school sports, MTBI occur most often in football, which accounts for over 
60% of high school concussions (Bailes, 2015).  For high school athletes, the leading 
cause of concussion for males is football and for females is soccer (Bailes, 2015).  The 
number one cause of death in sports is due to brain injuries (Bales, 2015).  In football, 
brain injuries account for 65 to 95% of all fatalities (Bailes, 2015).  TBI is the number 
one cause of death in children and young adults and causes 1.5 times more deaths than 
AIDS (Bailes, 2015).   
 
History of MTBI in American Football 
The great Greek physician and father of medicine, Hippocrates, made the first 
acknowledgement and diagnosis of a concussion around 400 B.C. (Maroon et al., 2014).  
It wasn’t until the early 1900’s that a revitalized opinion on current concussions including 
prevention and management occurred with President Theodore Roosevelt as the main 
visionary (Maroon et al., 2014).  The American football field was considered a war zone 
in the early 20th century where many injuries were catastrophic including skull fractures, 
	  6 
subdural and epidural hematomas, and twisted spinal cords (Maroon et al., 2014).  The 
sport was creating multiple deaths and hundreds of serious injuries per year (Maroon et 
al., 2014).  President Roosevelt, who was an avid proponent of physical competition, 
fitness, and teamwork, gathered the leading football schools and took steps to reduce the 
number of serious injuries (Maroon et al., 2014).  The National Collegiate Athletic 
Association (NCAA) was formed in the early 1900’s, which took further steps to create 
restrictive rules in football leading to a sharp decline in fatalities and serious injuries 
(Maroon et al., 2014).  The NCAA set the ground works for many changes in contact 
sports later on in the 20th century to reduce injury, specifically concussions (Maroon et 
al., 2014).  
 In the 1970’s, Dr. Joseph Maroon and Dr. James McMaster, team neurosurgeons 
for the Pittsburgh Steelers (football) and the Pittsburgh Panthers (hockey), respectively, 
focused their efforts on reducing and preventing the incidence of catastrophic head and 
neck injuries in contact sports (Maroon et al., 2014).  Their primary focus was to not miss 
rare fatal brain injuries having the thought that all MTBI would resolve with time 
(Maroon et al., 2014).  In the late 1980’s and early 1990’s, the two physicians found 
staggering results that the majority of athletes who sustain MTBI did not respond solely 
to time and their brains did not sufficiently heal (Maroon et al., 2014).  The majority of 
athletes had post-concussive syndrome where their symptoms would diminish, but 
continue for periods longer than expected (Maroon et al., 2014).   
 In the 1980’s, Dr. Maroon created the first objective concussion test, the 
Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) (Maroon, et 
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al., 2014).  The ImPACT program is a computerized neuropsychological testing tool that 
tests attention, memory, processing speed, and reaction time (Pellman et al., 2006).  
ImPACT testing first evaluates the baseline neurocognition of contact sport athletes and 
reapplies the same test after trauma in order to note any decline in neurocognitive 
function (Pellman et al., 2006).  ImPACT when paired with clinical judgment and a 
normal neurological examination, has been a very important tool diagnosing concussions 
and making return-to-play decisions (Maroon et al., 2014).  Another tool developed 
alongside ImPACT was the Sway Balance test, which assess balance function of athletes 
following injury (Maroon et al., 2014). 
 In 1994, the Mild Traumatic Brain Injury Committee was established by the 
National Football League (NFL) Commissioner, Paul Tagliabue (Maroon et al., 2014).  
The committee’s main purpose was to investigate cause of concussions, improve 
equipment to prevent concussions, and discuss rule changes to prevent head injury 
(Maroon et al., 2014).  In 2007, the NFL, for the first time, chose a universal 
neurocognitive testing method as part of evaluation for all team trainers and physicians – 
the ImPACT test (Maroon et al., 2014).  Since 2007, the NFL has been more stringent 
about protecting its athletes from concussions with rule changes, neurology specialists on 
the sideline, concussion phone hotlines, and improved equipment (Maroon et al., 2014).  
The NFL donated millions of dollars to the CDC in 2011 to promote concussion 
awareness and research (Maroon et al., 2014).  As concussions continue to occur, more 
research is focused on prevention, treatment, and how to reduce long-term effects 
(Gardner et al., 2015).  
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Facts and History of CTE 
Current studies show at least seventeen percent of individuals that suffered from 
repetitive MTBI develop CTE, but the number is likely much higher due to the precise 
incidence being unknown (McKee et al., 2009).  CTE was first introduced by Dr. 
Harrison Martland in 1928 with the term “punch-drunk syndrome” that was the result of 
multiple blows to the head (McKee et al., 2009).  The term later evolved into “dementia 
pugilistica” by Dr. Millspaugh (Mckee et al., 2009).  The brain of one suffering from 
CTE gradually deteriorates over time with certain areas prone to atrophy and others 
becoming exceptionally enlarged (Bailes, 2015).  In CTE, areas of the brain accrue a 
large amount of tau protein, a substance that serves to stabilize cellular structure in the 
neurons, but which may become defective and may cause major interference with the 
function of the neurons (Bailes, 2015).  
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PUBLISHED STUDIES 
Symptoms of MTBI 	   With the brain playing an important role in all functions of the body, an injury to 
the head including MTBI can cause widespread issues (Bailes, 2015).  Symptoms often 
express themselves physically, cognitively, emotionally, and through disrupted sleep 
patterns (Resch et al., 2015).  Symptoms include headaches, dizziness, nausea and 
vomiting, light sensitivity, loss of balance, lethargy, sadness, anxiety, irritability, 
volatility, and lack of concentration as well as other symptoms mentioned in Table 2 
(Broglio et al., 2007, “Impact Test”).  MTBI often result in trouble concentrating, 
thinking clearly, and in short-term memory loss (Bailes, 2015).  The sub-populations 
most at risk for MTBI and consequently, repetitive MTBI are contact sport athletes 
including football, boxing, hockey, and soccer, as well as military personal and victims of 
domestic violence (Gardner et al., 2015).  The prevalence of exposure to MTBI in the 
sub-populations with higher risk have however followed a “secular trend”, where the 
average length of career of those athletes has decreased by nearly 75% and the thus the 
number of games played has decreased similarly (Gardner et al., 2015).  MTBI are 
commonly evaluated with a clinical examination and the athlete’s report of post-
concussion symptoms (Broglio et al., 2007).  The symptoms vary tremendously in onset, 










Diagnosis of MTBI In Contact Sport Athletes A.	  Neurological	  and	  Musculoskeletal	  Physical	  Examination	   	  The	  trouble	  with	  diagnosing	  MTBI	  in	  contact	  sport	  athletes	  is	  that	  here	  is	  no	  single,	  definitive	  test	  that	  determines	  if	  an	  athlete	  has	  MTBI	  (Pellman	  et	  al.,	  2006).	  	  	  Instead,	  team	  trainers	  and	  physicians	  must	  use	  a	  combination	  of	  examinations	  and	  tests	  in	  order	  to	  make	  a	  diagnosis	  and	  decision	  on	  return-­‐to-­‐play	  for	  the	  individual	  athlete	  (Pellman	  et	  al.,	  2006).	  	  The	  immediate	  golden	  standard	  for	  MTBI	  testing	  remains	  the	  neurological	  and	  musculoskeletal	  physical	  examination	  of	  an	  athlete	  by	  a	  team	  trainer	  or	  physician	  (Broglio	  et	  al.,	  2007).	  	  Team	  trainers	  and	  physicians	  will	  take	  ask	  questions	  regarding	  the	  injury	  to	  better	  determine	  the	  severity	  and	  significance	  (Pellman	  et	  al.,	  2007).	  	  Questions	  include	  symptom	  onset,	  duration,	  quality,	  associated	  symptoms,	  and	  severity	  (Pellman	  et	  al.,	  2007).	  	  Not	  only	  are	  they	  taking	  in	  the	  specifics	  of	  the	  information	  provided	  by	  the	  athlete,	  but	  the	  physicians	  are	  also	  looking	  at	  how	  the	  questions	  are	  answered	  to	  see	  if	  there	  may	  be	  any	  immediate	  cognitive	  impairment	  (Pellman	  et	  al.,	  2007).	  	  The	  neurological	  physical	  exam	  includes	  testing	  of	  higher	  functions,	  cranial	  nerves,	  the	  sensory	  system,	  the	  motor	  system,	  reflexes,	  the	  cerebellum,	  and	  meninges	  (Pellman	  et	  al.,	  2007).	  	  The	  neurological	  physical	  exam	  may	  provide	  the	  best	  short-­‐term	  diagnosis	  and	  answer	  about	  whether	  return-­‐to-­‐play	  is	  acceptable,	  but	  it	  is	  recommended	  that	  athletes	  showing	  any	  signs	  or	  symptoms	  of	  MTBI	  be	  put	  through	  additional	  testing	  to	  supplement	  the	  physical	  exam	  (Broglio	  et	  al.,	  2007).	  B.	  VOMS	  Testing	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It	  is	  often	  found	  that	  athletes	  suffering	  from	  MTBI	  have	  vestibular	  and	  ocular	  motor	  impairments	  and	  symptoms	  (Mucha	  et	  al.,	  2014).	  	  A	  recent	  study	  intended	  to	  create	  a	  consistent	  and	  brief	  clinical	  screening	  tool	  for	  vestibular	  and	  ocular	  motor	  impairments	  called	  the	  Vestibular/Ocular	  Motor	  Screening	  (VOMS)	  assessment	  (Mucha	  et	  al.,	  2014)	  (Table	  3).	  	  Sixty-­‐four	  patients	  and	  seventy-­‐eight	  controls	  were	  administered	  the	  VOMS	  test	  within	  5	  days	  of	  an	  MTBI	  (Mucha	  et	  al.,	  2014).	  	  The	  VOMS	  included	  assessments	  in	  smooth	  pursuit,	  horizontal	  and	  vertical	  saccades,	  convergence,	  horizontal	  vestibular	  ocular	  reflex,	  and	  visual	  motion	  sensitivity	  (Mucha	  et	  al.,	  2014).	  	  Patients	  would	  verbally	  rate	  changes	  in	  headache,	  dizziness,	  nausea,	  and	  fogginess	  symptoms	  compared	  with	  their	  immediate	  pre-­‐assessment	  score	  from	  1-­‐10	  after	  each	  VOMS	  assessment	  to	  determine	  if	  each	  assessment	  provokes	  symptoms	  (Mucha	  et	  al.,	  2014).	  	  	  
	  
Table	  3	  VOMS	  Assessment	  Domains	  for	  Symptom	  Provocation	  and	  Total	  Symptom	  Scores	  in	  Concussed	  Patients	  and	  Healthy	  Controls	  (Mucha	  et	  al.,	  2014)	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   The	  study	  shows	  that	  sixty-­‐one	  percent	  of	  patients	  reported	  symptom	  provocation	  after	  at	  least	  1	  VOMS	  item	  and	  that	  all	  VOMS	  items	  were	  positively	  correlated	  to	  the	  Post-­‐Concussion	  Symptom	  Scale	  (Mucha	  et	  al.,	  2014).	  	  Figure	  3	  shows	  that	  the	  VOMS	  test	  can	  be	  used	  to	  diagnose	  an	  MTBI	  as	  the	  movements	  often	  provoke	  MTBI	  symptoms	  (Mucha	  et	  al.,	  2014).	  	  A	  near	  point	  of	  convergence	  distance	  of	  greater	  than	  five	  cm	  increased	  the	  probability	  of	  correctly	  identifying	  concussed	  patients	  (Mucha	  et	  al.,	  2014).	  	  	  VOMS	  demonstrated	  high	  sensitivity,	  meaning	  that	  a	  positive	  test	  result	  was	  very	  accurate	  in	  identifying	  athletes	  who	  experiences	  MTBI	  (Mucha	  et	  al.,	  2014).	  	  The	  study	  shows	  that	  patients	  with	  impairments	  and	  symptoms	  in	  vestibular	  and	  ocular	  motor	  function	  after	  sport-­‐related	  MTBI	  can	  be	  identified	  and	  that	  it	  may	  lead	  to	  better	  targeted	  vestibular	  rehabilitation	  (Mucha	  et	  al.,	  2014).	  	  Vestibular	  rehabilitation	  has	  been	  proven	  to	  manage	  diseases	  such	  as	  benign	  paroxysmal	  positional	  vertigo,	  vestibular	  hypofunction,	  migraine-­‐related	  dizziness,	  and	  central	  vestibular	  disorders	  (Mucha	  et	  al.,	  2014).	  	  With	  improved	  VOMS	  testing	  providing	  a	  more	  targeted	  approach	  with	  MTBI,	  vestibular	  rehab	  may	  support	  the	  dizziness,	  balance	  and	  vestibulo-­‐ocular	  impairments	  following	  MTBI	  (Mucha	  et	  al.,	  2014).	  	  	  C.	  ImPACT	  Test	  	   Another	  major	  contributor	  to	  the	  diagnosis	  of	  MTBI	  alongside	  the	  physical	  examination	  and	  VOMS	  testing	  is	  the	  Immediate Post-Concussion Assessment 
Cognitive Testing (ImPACT) (“ImPACT Test”).  The ImPACT test is computerized and 
takes about 25 minutes to complete (“ImPACT Test”).  Baseline measurements are taken 
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on athletes at least every two years to ensure accuracy and to serve as a comparison to a 
repeat test, which professionals use to assess changes or damages caused by MTBI 
(“ImPACT Test”).   
The program measures multiple aspects of cognitive functioning for athletes 
including attention span, working memory, sustained and selective attention, response 
variability, non-verbal problem solving, and reaction time (“ImPACT Test”).  The 
ImPACT test contains three major sections – a demographic profile and health history 
questionnaire, current concussion symptoms and conditions, and the neurocognitive 
testing (“ImPACT Test”).  The demographic profile section provides information about 
the athlete’s height, weight, sport, position, concussion history, and history of learning 
disabilities or other important information (“ImPACT Test”).  The current concussion 
symptoms and conditions portion provides information about the most recent concussion, 
sleep patterns, and current medications, and the participant rates current severity of 
twenty-two concussion related symptoms (“ImPACT Test”).  There are 6 modules of the 
neurocognitive testing (“ImPACT Test”).  Module 1, word discrimination evaluates 
attentional processes and verbal recognition memory (“ImPACT Test”).  Module 2, 
design memory, evaluates attentional processes and visual recognition memory 
(“ImPACT Test”).  Module 3, X’s and O’s, measures visual working memory as well as 
visual processing speed (“ImPACT Test”).  Module 4, symbol matching, evaluates visual 
processing speed, learning, and memory (“ImPACT Test”).  Module 5, color match, 
evaluates reaction time, impulse control, and response inhibition (“ImPACT Test”).  
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Module 6, three letter memory, evaluates working memory and visual-motor response 
speed (“ImPACT Test”).   
A study by Dr. Yusuke Nakayama looked to re-examine the test-retest reliability 
of ImPACT between baseline, 45 days, and 50 days (Nakayama et al., 2014).  The study 
consisted of eighty-five physically active college students that completed the ImPACT 
test at baseline, 45 days, and 50 days to ensure its reliability (Nakayama et al., 2014).  
The results showed that all areas exceeded the threshold value for acceptable test-retest 
reliability, suggesting that the ImPACT test is a reliable neurocognitive test at 45 and 50 
days after baseline assessment (Nakayama et al., 2014).   
Recent developments with VOMS and ImPACT tests have improved trainers and 
physician’s ability to distinguish and diagnose MTBI in contact sport athletes (Broglio et 
al., 2007, Mucha et al., 2014).  Most current studies recognize that the individual tests 
alone are not sufficient enough to provide a clear diagnosis of MTBI and relay return-to-
play protocols (Nakayama et al., 2014).  It is suggested that the neurological physical 
examination be administered to each athlete suspected of MTBI, but also that both 
VOMS and ImPACT testing be administered to the athlete to better determine a diagnosis 
and a return-to-play timeframe (Broglio et al., 2007).  The National Football League 
(NFL) and its Mild Traumatic Brain Injury Committee were the first to standardize the 
use of ImPACT testing for each individual athlete and made it mandatory alongside a 
neurological physical exam by team physicians (Maroon et al., 2014).  After the NFL’s 
testing stance, many high schools and colleges throughout the country followed suit, 
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creating a more vigilant atmosphere in diagnosing concussions in athletes (Maroon et al., 
2014). 	  
Symptoms and Return to Play  
Team physicians and trainers rely on the athlete’s accurate reporting of symptoms 
both immediately after a traumatic injury and in the days and weeks following the injury 
(Broglio et al., 2007).  The two main issues in dealing with concussions are the timing of 
symptom resolution and unreported symptoms leading to untreated athletes (Broglio et 
al., 2007, Resch et al., 2015).  Dr. Jacob Resch and his team designed a cross-sectional 
study of at two NCAA Division I universities to look at symptom presentation and 
recovery after an MTBI (Resch et al., 2015).  Participants completed the Revised Head 
Injury Scale (HIS-r), Immediate Post-Concussion Assessment Cognitive Testing 
(ImPACT), and Sensory Organization Testing first prior to the MTBI as a baseline score 
and then within 24 hours of an MTBI (Resch et al., 2015).   
The HIS-r consists of 22 symptoms related to MTBI and participants would circle 
either yes or no depending on if they were or were not experiencing the symptom (Resch 
et al., 2015) (Table 4).  With any yes response, the participant would rate the duration and 
severity of the symptom, and the duration and severity were then summed to find a total 
score (Resch et al., 2015).   
The ImPACT test measured attention, memory, reaction time, and information-
processing speed consisting of 8 tests (Resch et al., 2015) (Table 4).  The Sensory 
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Organization Test assesses postural stability to determine a balance and equilibrium score 
based on visual, vestibular, somatosensory, and visual conflict (Resch et al., 2015).   
 
Table 4 Symptom Duration Testing Areas 
 
(Resch et al., 2015) 	   The	  study’s	  final	  formula	  consisted	  of	  the	  HIS-­‐r’s	  symptoms	  of	  neck	  pain,	  drowsiness,	  tingling,	  and	  nervousness	  as	  well	  as	  the	  ImPACT	  total	  symptom	  severity	  (Resch	  et	  al.,	  2015).	  	  The	  formula	  identified	  that	  76%	  of	  the	  participants	  recovered	  within	  10	  days	  of	  injury	  (Resch	  et	  al.,	  2015).	  	  The	  study	  also	  noted	  that	  there	  was	  a	  considerable	  amount	  of	  variance	  associated	  with	  days	  symptomatic	  after	  MTBI	  for	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the	  participants	  and	  that	  the	  10	  day	  prediction	  should	  be	  used	  clinically	  with	  caution	  (Resch	  et	  al.,	  2015).	  	  	  
	  
Table	  5	  Descriptive	  Statistics	  for	  Symptom	  Duration	  Study	  
	  
 
(Resch et al., 2015) 
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 Dr. Steven Broglio and his team designed a study to look at the neurocognitive 
performance of athletes who have had a recent MTBI, but are now symptom free 
(Broglio et al., 2007).  A major issue with MTBI, and especially repetitive MTBI is the 
underreporting of concussion-related symptoms by athletes in order to expedite their 
return to play (Broglio et al., 2007).  With team physicians and trainers relying on 
reported symptoms when making return-to-play decisions, underreporting those 
symptoms may lead to subsequent injury if complete recovery has not been made 
(Broglio et al., 2007).  The study included twenty-one NCAA Division I athletes with 
recent MTBI and the ImPACT concussion assessment test was administered at baseline, 
when symptomatic, and when asymptomatic in order to assess verbal memory, visual 
memory, visual-motor speed, reaction time, and concussion related symptoms (Broglio et 
al., 2007).  
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Table 6 Results on the ImPACT and Symptom Scale for All Concussed Athletes
 (Broglio	  et	  al.,	  2007).	  
	  
Table	  7	  Results	  on	  ImPACT	  and	  Symptom	  Scale	  for	  All	  Concussed	  Athletes	  Evaluated	  at	  Asymptomatic	  Assessment	  Point	  
	  (Broglio	  et	  al.,	  2007).	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   Based	  on	  reported	  symptoms	  and	  duration	  of	  symptoms,	  athletes	  were	  determined	  to	  have	  simple	  or	  complex	  concussions	  (Broglio	  et	  al.,	  2007).	  	  Table	  6	  shows	  the	  results	  from	  testing	  at	  baseline,	  self-­‐reported	  symptomatic,	  and	  self-­‐reported	  asymptomatic	  stages	  (Broglio	  et	  al.,	  2007).	  	  At	  the	  symptomatic	  self-­‐reported	  time	  point,	  the	  results	  showed	  that	  seventeen	  athletes	  of	  the	  twenty-­‐one	  tested	  (81%)	  were	  impaired	  on	  at	  least	  one	  cognitive	  or	  symptom	  variable	  based	  on	  either	  the	  ImPACT	  testing	  or	  Symptom	  Assessment	  Scale	  (Broglio	  et	  al.,	  2007).	  	  At	  the	  asymptomatic	  self-­‐reported	  time	  frame	  (Table	  7),	  no	  athlete	  reported	  any	  MTBI-­‐related	  symptoms,	  but	  the	  results	  still	  showed	  eight	  athletes	  (38%),	  including	  6	  athletes	  with	  simple	  concussions	  and	  2	  athletes	  with	  complex	  concussions	  showing	  continued	  impairment	  on	  at	  least	  one	  cognitive	  variable	  relative	  to	  baseline	  (Broglio	  et	  al.,	  2007).	  	  	  	   A	  significant	  number	  of	  athletes	  continued	  to	  show	  poor	  test	  performance	  and	  cognitive	  impairment	  although	  they	  denied	  concussion-­‐related	  symptoms	  (Broglio	  et	  al.,	  2007).	  	  This	  study	  by	  Broglio	  and	  his	  colleagues	  strongly	  contrasts	  that	  by	  Resch	  and	  his	  colleagues	  who	  predicted,	  but	  cautioned	  a	  10-­‐day	  response	  period	  to	  MTBI	  (Broglio	  et	  al.,	  2007,	  Resch	  et	  al.,	  2015).	  	  With	  a	  significant	  number	  of	  athletes	  continue	  with	  cognitive	  impairment,	  a	  more	  conservative	  approach	  to	  return-­‐to-­‐play	  decision	  making	  would	  more	  than	  likely	  benefit	  the	  athletes	  and	  reduce	  the	  risk	  for	  repetitive	  MTBI	  (Broglio	  et	  al.,	  2007).	  	  Broglio	  also	  undermined	  the	  notion	  of	  simple	  versus	  complex	  concussions	  with	  the	  fact	  that	  a	  greater	  percentage	  of	  “simple	  concussion	  athletes”	  (28%	  versus	  9%)	  were	  found	  to	  have	  
	  22 
neurocognitive	  impairment	  in	  the	  asymptomatic	  self-­‐reporting	  stage	  (Broglio	  et	  al.,	  2007).	  	  The	  study	  thus	  suggests	  that	  there	  should	  not	  be	  a	  distinction	  between	  simple	  and	  complex	  concussions	  when	  making	  return-­‐to-­‐play	  decisions	  (Broglio	  et	  al.,	  2007).	  	  It	  is	  suggested	  that	  alongside	  self-­‐reported	  symptoms	  of	  athletes,	  that	  neurocognitive	  testing	  should	  be	  applied	  to	  all	  athletes	  suspected	  of	  suffering	  from	  MTBI	  (Broglio	  et	  al.,	  2007).	  	  The	  clinical	  exam	  continues	  to	  be	  the	  greatest	  interpretation	  of	  MTBI	  and	  should	  be	  considered	  the	  “gold	  standard”	  of	  return-­‐to-­‐play	  decision-­‐making,	  with	  self-­‐reported	  symptoms	  and	  neurocognitive	  testing	  serving	  to	  support	  the	  clinical	  exam	  (Broglio	  et	  al.,	  2007).	  	  	  	   Faulty	  return-­‐to-­‐play	  decision-­‐making	  can	  result	  in	  repetitive	  MTBI	  and	  may	  lead	  to	  further	  brain	  injury,	  which	  warrants	  further	  investigation	  into	  symptom	  resolution	  and	  neurocognitive	  function	  (Broglio	  et	  al.,	  2007).	  	  A	  beneficial	  investigation	  would	  include	  researching	  the	  incidence	  of	  concussed	  athletes	  underreporting	  their	  symptoms	  (Broglio	  et	  al.	  ,	  2007).	  	  Underreporting	  may	  be	  due	  to	  not	  wanting	  to	  leave	  the	  game,	  fear	  of	  letting	  teammates	  down,	  or	  being	  generally	  unaware	  of	  signs	  and	  symptoms	  of	  MTBI,	  all	  of	  which	  put	  the	  athlete	  at	  increased	  risk	  (Broglio	  et	  al.,	  2007).	  	  	  	  
Repetitive MTBI and the Development of Chronic Traumatic Encephalopathy  	   Underreported	  symptoms	  of	  MTBI,	  poor	  return-­‐to-­‐play	  guidelines,	  and	  simply	  increased	  exposure	  to	  head	  trauma	  via	  extended	  careers	  of	  contact	  sport	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athletes	  has	  led	  to	  repeat	  MTBI	  and	  in	  some	  cases,	  to	  Chronic	  Traumatic	  Encephalopathy	  (CTE)	  (Broglio	  et	  al.,	  2007,	  McKee	  et	  al.,	  2009).	  	  	  Repetitive	  head	  injuries	  occur	  in	  a	  wide	  variety	  of	  contact	  sports	  including	  football,	  boxing,	  wrestling,	  rugby,	  hockey,	  lacrosse,	  soccer,	  and	  skiing	  (McKee	  et	  al.,	  2009).	  	  Repetitive	  MTBI	  and	  cases	  of	  CTE	  are	  most	  well	  known	  in	  boxing,	  but	  have	  also	  been	  verified	  in	  professional	  football	  players,	  wrestling,	  and	  soccer	  as	  well	  as	  in	  epileptics	  and	  domestic	  abuse	  victims	  so	  far	  (McKee	  et	  al.,	  2009).	  	  Of	  the	  neuropathologically	  confirmed	  cases	  of	  CTE,	  ninety	  percent	  occurred	  in	  athletes,	  with	  eighty-­‐five	  percent	  occurring	  in	  boxers	  and	  eleven	  percent	  occurring	  in	  professional	  football	  players	  (McKee	  et	  al.,	  2009).	  	  All	  of	  the	  confirmed	  cases	  were	  of	  athletes	  that	  began	  their	  respective	  sports	  at	  young	  ages	  between	  eleven	  and	  nineteen	  years	  old	  and	  the	  first	  signs	  of	  symptoms	  began	  at	  ages	  ranging	  from	  twenty-­‐five	  to	  seventy-­‐six	  years	  old	  	  (McKee	  et	  al.,	  2009).	  	  Two	  third	  of	  the	  confirmed	  cases	  were	  asymptomatic	  at	  the	  time	  of	  retirement,	  but	  nearly	  half	  were	  symptomatic	  within	  four	  years	  of	  stopping	  play	  (McKee	  et	  al.,	  2009).	  	  	  The	  symptoms	  of	  CTE	  are	  first	  manifested	  by	  deteriorations	  in	  attention,	  concentration,	  and	  memory,	  and	  also	  include	  disorientation	  and	  confusion	  as	  well	  as	  associated	  dizziness	  and	  headaches	  (McKee	  et	  al.,	  2009).	  	  As	  the	  disease	  progresses,	  additional	  symptoms	  become	  apparent	  including	  lack	  of	  insight,	  poor	  judgment,	  and	  overt	  dementia	  (McKee	  et	  al.,	  2009).	  	  More	  advanced	  cases	  of	  CTE	  have	  individuals	  with	  a	  progressive	  slowing	  of	  muscular	  movements,	  a	  staggered	  propulsive	  gait,	  masked	  facies,	  impeded	  speech,	  tremors,	  vertigo,	  and	  deafness	  (McKee	  et	  al.,	  2009).	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An	  individual	  with	  CTE	  may	  mistake	  his/her	  symptoms	  with	  the	  normal	  aging	  process	  or	  may	  receive	  a	  wrong	  diagnosis	  due	  to	  similar	  symptoms	  to	  Alzheimer’s	  or	  Parkinson’s	  disease	  (McKee	  et	  al.,	  2009).	  	  CTE	  has	  been	  broken	  down	  into	  three	  stages	  of	  clinical	  deterioration	  in	  past	  studies	  (McKee	  et	  al.,	  2009).	  	  The	  first	  stage	  is	  typified	  by	  affective	  disturbances	  and	  psychotic	  symptoms	  (McKee	  et	  al.,	  2009).	  	  The	  second	  stage	  is	  characterized	  by	  social	  instability,	  erratic	  behavior,	  memory	  loss,	  and	  initial	  symptoms	  of	  Parkinson’s	  disease	  including	  tremor	  and	  slowing	  of	  muscular	  movements	  (McKee	  et	  al.,	  2009).	  	  The	  third	  stage	  includes	  general	  cognitive	  dysfunction	  progressing	  to	  dementia	  and	  is	  often	  accompanied	  by	  parkinsonism,	  as	  well	  as	  speech	  and	  gait	  abnormalities	  (McKee	  et	  al.,	  2009).	  	  The	  severity	  of	  CTE	  seems	  to	  correlate	  with	  the	  number	  of	  MTBI	  suffered	  and	  the	  length	  of	  time	  engaged	  in	  the	  sport	  (McKee	  et	  al.,	  2009).	  Some	  of	  the	  most	  disturbing	  symptoms	  associated	  with	  CTE	  are	  with	  the	  behavior	  of	  the	  individual	  including	  major	  depression,	  neuropsychiatric	  issues,	  and	  cognitive	  impairment	  (Omalu,	  2010).	  	  The	  symptoms	  are	  most	  often	  associated	  with	  more	  severe	  and	  progressed	  cases	  of	  CTE,	  but	  can	  come	  on	  suddenly	  and	  are	  most	  often	  noticed	  by	  family	  members	  (Omalu,	  2010).	  	  Dr.	  Omalu	  created	  a	  case	  study	  of	  five	  individuals	  who	  previously	  played	  contact	  sport	  athletes,	  were	  diagnosed	  with	  CTE	  postmortem,	  and	  who	  all	  committed	  suicide	  (Omalu,	  2010).	  	  He	  determined	  that	  individuals	  who	  have	  CTE	  are	  at	  increased	  risk	  for	  suicide	  and/or	  parasuicide	  due	  to	  the	  symptoms	  of	  major	  depression,	  neuropsychiatric	  issues,	  and	  cognitive	  impairment	  present	  in	  severe	  cases	  of	  CTE	  (Omalu	  et	  al.,	  2010).	  	  Table	  8	  identifies	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common	  behavioral	  and	  neurocognitive	  symptoms	  present	  in	  the	  five	  athletes	  who	  committed	  suicide,	  determining	  CTE	  as	  a	  common	  risk	  factor	  (Omalu,	  2010).	  	  	  	  
Table	  8	  Behavioral	  Features	  Identified	  in	  Confirmed	  Cases	  of	  CTE	  	  
	  (Omalu,	  2010)	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Diagnosis and Pathology of CTE 	   There	  are	  major	  limitations	  in	  the	  study	  of	  CTE	  and	  its	  correlation	  to	  MTBI	  (Gardner	  et	  al.,	  2015).	  	  Some	  of	  the	  limitations	  include	  lack	  of	  consensus	  clinical	  criteria	  for	  CTE,	  objective	  quantification	  and	  measurement	  of	  repetitive	  MTBI	  exposure	  is	  difficult,	  recall	  bias,	  selection/referral	  bias,	  finding	  an	  appropriate	  control	  group,	  and	  the	  fact	  that	  symptoms	  of	  CTE	  may	  not	  appear	  until	  years	  or	  decades	  following	  MTBI	  exposure	  (Gardner	  et	  al.,	  2015).	  	  But	  the	  major	  limitation	  in	  studying	  CTE	  is	  in	  regards	  to	  its	  diagnosis	  (Azad	  et	  al.,	  2015).	  	  Currently,	  a	  diagnosis	  of	  CTE	  can	  only	  be	  confirmed	  and	  accurately	  established	  via	  autopsy	  (Azad	  et	  al.,	  2015).	  	  Recent	  efforts	  have	  focused	  on	  attempting	  to	  create	  an	  in	  vivo	  diagnosis	  method	  of	  CTE	  in	  order	  to	  conduct	  research	  on	  risk	  factors	  and	  epidemiology	  and	  in	  order	  to	  perform	  clinical	  trials	  for	  proper	  prevention	  and	  treatment	  of	  CTE	  (Azad	  et	  al.,	  2015).	  	  	  CTE	  is	  defined	  as	  a	  neurodegenerative	  disease	  pathologically	  confirmed	  by	  the	  presence	  of	  a	  unique	  pattern	  of	  hyperphosphorylated	  tau	  neurofibrillary	  and	  astrocytic	  tangles	  in	  the	  brain	  (Azad	  et	  al.,	  2015).	  	  The	  diagnosis	  criteria	  for	  CTE	  includes	  four	  parts,	  (i.)	  perivascular	  foci	  of	  phosphorylated-­‐tau	  immunoreactive	  astrocytic	  tangles	  and	  neurofibrillary	  tangles,	  (ii.)	  irregular	  cortical	  distribution	  of	  p-­‐tau	  immunoreactive	  neurofibrillary	  tangles	  and	  astrocytic	  tangles	  with	  a	  predilection	  for	  the	  depth	  of	  cerebral	  sulci,	  (iii.)	  clusters	  of	  subpial	  and	  periventricular	  astrocytic	  tangles	  in	  the	  cerebral	  cortex,	  diencephalon,	  basal	  ganglia,	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and	  brainstem,	  and	  (iv.)	  neurofibrillary	  tangles	  in	  the	  cerebral	  cortex	  located	  preferentially	  in	  the	  superficial	  layers	  (Azad	  et	  al.,	  2015,	  McKee,	  2013).	  	  The	  tau-­‐immunoreactive	  neurofibrillary	  tangles	  is	  irregular	  in	  distribution	  with	  multifocal	  patches	  of	  dense	  neurofibrillary	  tangles	  in	  the	  superficial	  cortical	  layers	  (McKee,	  2013).	  	  Abnormal	  accumulations	  of	  malformed	  TAR	  DNA-­‐binding	  protein	  43	  are	  also	  observed	  in	  CTE	  (Azad	  et	  al.,	  2015).	  	  Neurofibrillary	  degeneration	  most	  often	  leads	  to	  neuronal	  loss	  and	  gliosis,	  which	  is	  most	  pronounced	  in	  the	  hippocampus,	  the	  entorhinal	  cortex,	  and	  the	  amygdala	  areas	  of	  the	  brain	  (McKee	  et	  al.,	  2009).	  	  In	  advanced	  CTE,	  neuronal	  loss	  and	  gliosis	  is	  also	  found	  in	  the	  subcallosal	  and	  insular	  cortex,	  and	  less	  so	  in	  the	  frontal	  and	  temporal	  cortex	  (McKee	  et	  al.,	  2009).	  	  Other,	  less	  frequent	  areas	  of	  the	  brain	  that	  show	  neuronal	  loss	  include	  the	  mammilary	  bodies,	  medial	  thalamus,	  substantia	  nigra,	  locus	  caeruleus,	  and	  nucleus	  accumbens	  (McKee	  et	  al.,	  2009).	  	  	  A	  case	  study	  by	  Geddes	  focuses	  on	  the	  perivascular	  distribution	  of	  neurofibrillary	  tangles	  (Geddes,	  1999).	  	  The	  brains	  of	  5	  young	  men	  including	  2	  boxers,	  a	  soccer	  player,	  an	  epileptic	  patient,	  and	  a	  mentally	  subnormal	  patient	  with	  a	  long	  history	  of	  head	  banging	  were	  examined	  and	  diagnosed	  with	  CTE	  (Geddes,	  1999).	  	  All	  of	  the	  brains	  showed	  argyrophilic	  tau-­‐positive	  neocortical	  neurofibrillary	  tangles	  that	  were	  arranged	  around	  small	  intracortical	  blood	  vessels	  and	  around	  small	  arteries	  associated	  with	  neuropil	  and	  tau	  neurons	  (Geddes,	  1999).	  	  Geddes	  suggests	  that	  neurofibrillary	  tangles	  around	  penetrating	  vessels	  in	  sulci	  may	  be	  of	  ischaemic	  aetiology,	  which	  causes	  neuronal	  cytoskeleton	  degradation	  (Geddes,	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1999).	  	  The	  neurofibrillary	  tangles	  most	  likely	  cause	  damage	  to	  the	  vessels,	  making	  them	  permeable	  with	  repeated	  trauma	  (Geddes,	  1999).	  	  	  The	  gross	  pathological	  findings	  of	  CTE	  after	  diagnosis	  post-­‐mortem	  via	  autopsy	  include	  a	  reduction	  in	  brain	  weight,	  enlargement	  of	  the	  lateral	  and	  third	  ventricles,	  thinning	  of	  the	  corpus	  callosum,	  cavum	  septum	  pellucidum	  with	  fenestrations,	  and	  scarring	  and	  neuronal	  loss	  of	  the	  cerebellar	  tonsils	  (McKee	  et	  al.,	  2009).	  	  Most	  of	  the	  brain	  atrophy	  occurs	  in	  the	  frontal	  lobe	  (36%),	  temporal	  lobe	  (31%),	  and	  parietal	  lobe	  (22%)	  (McKee	  et	  al.,	  2009).	  	  The	  lateral	  ventricles	  (53%)	  and	  the	  III	  ventricles	  are	  often	  dilated	  (29%),	  while	  the	  IV	  ventricle	  is	  rarely	  enlarged	  (4%)	  (McKee	  et	  al.,	  2009).	  The	  symptoms	  of	  CTE	  cause	  the	  individuals	  suffering	  from	  the	  disease	  to	  often	  confuse	  it	  with	  the	  likes	  of	  Parkinson’s	  disease	  or	  Alzheimer’s	  disease	  (McKee	  et	  al.,	  2009).	  	  The	  accumulation	  pattern	  varies	  from	  the	  taupathy	  of	  Alzheimer’s	  disease	  due	  to	  the	  presence	  of	  tau	  astrocytes,	  which	  are	  not	  present	  in	  Alzheimer’s	  disease	  (Azad	  et	  al.,	  2015).	  	  On	  the	  other	  hand,	  Alzheimer’s	  disease	  is	  characterized	  by	  beta	  amyloid	  neuritic	  plaques	  (Azad	  et	  al.,	  2015).	  	  Parkinson’s	  disease	  is	  better	  characterized	  with	  the	  presence	  and	  distribution	  of	  alpha-­‐synuclein-­‐positive	  Lewy	  Bodies	  and	  is	  brainstem	  dominant	  (McKee,	  2013).	  	  	  
	  29 
Table	  9	  Proposed	  Staging	  of	  CTE	  	  
	  (Azad	  et	  al.,	  2015)	  	   Table	  9	  shows	  the	  four	  stages	  of	  CTE	  and	  the	  brief	  pathology	  associated	  with	  each	  stage	  (Azad	  et	  al.,	  2015).	  	  Stage	  one	  CTE	  is	  characterized	  mainly	  by	  perivascular	  tau	  neurofibrillary	  and	  astrocytic	  tangles	  in	  the	  sulcal	  depths	  of	  superior	  and	  sorsolateral	  frontal	  cortices	  (McKee,	  2013).	  	  There’s	  no	  significant	  change	  in	  brain	  weight	  or	  gross	  pathology	  during	  the	  first	  stage	  (McKee,	  2013).	  	  Symptomatically,	  stage	  one	  CTE	  most	  often	  involves	  headache,	  short-­‐term	  memory	  difficulties,	  increased	  aggression,	  and	  depression	  (McKee,	  2013).	  	  Stage	  two	  CTE	  is	  characterized	  increased	  tau	  pathology	  in	  the	  cortex	  including	  the	  superior,	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dorsolateral,	  lateral,	  inferior,	  and	  subcollosum	  (McKee,	  2013).	  	  There’s	  no	  evidence	  of	  brain	  tissue	  atrophy	  in	  stage	  two,	  but	  there	  are	  cases	  of	  enlargement	  of	  the	  lateral	  ventricles	  and	  third	  ventricles	  (McKee,	  2013).	  	  Clinically,	  stage	  two	  CTE	  individuals	  typically	  showed	  depression,	  mood	  swings,	  headache,	  and	  short-­‐term	  memory	  loss,	  but	  other	  symptoms	  also	  include	  explosivity	  and	  loss	  of	  attention	  and	  concentration	  (McKee,	  2013).	  	  Stage	  three	  CTE	  is	  characterized	  by	  extensive	  tau	  pathology	  and	  significant	  brain	  atrophy	  as	  noted	  in	  the	  Figure	  9	  (Azad	  et	  al.,	  2015).	  	  	  Symptoms	  of	  stage	  three	  CTE	  most	  commonly	  included	  memory	  loss,	  executive	  dysfunction,	  explosivity,	  and	  lack	  of	  attention	  and	  concentration,	  but	  also	  included	  depression,	  mood	  swings,	  visuospatial	  difficulties,	  and	  significant	  aggression	  (McKee,	  2013).	  	  Suicide	  intentions	  were	  also	  present	  in	  individuals	  who	  suffered	  from	  stage	  three	  CTE	  (McKee,	  2013).	  	  Individuals	  who	  suffered	  from	  stage	  four	  CTE,	  the	  most	  severe	  form	  of	  the	  disease,	  presented	  with	  increased	  spread	  of	  tau	  pathology	  in	  the	  brain	  and	  into	  the	  spinal	  cord,	  substantial	  neuronal	  loss,	  and	  significant	  atrophy	  of	  multiple	  areas	  of	  the	  brain	  (McKee,	  2013).	  	  Clinically,	  all	  individuals	  with	  stage	  four	  CTE	  developed	  severe	  memory	  loss	  with	  dementia,	  and	  most	  had	  executive	  dysfunction,	  loss	  of	  attention	  and	  concentration,	  language	  difficulties,	  explosivity,	  aggression,	  paranoia,	  depression,	  gait	  abnormalities,	  and	  visuospatial	  difficulties	  (McKee,	  2013).	  	  Some	  stage	  four	  CTE	  individuals	  developed	  Parkinson’s	  disease	  (McKee,	  2013).	  	  Nearly	  a	  third	  of	  the	  individuals	  with	  stage	  four	  CTE	  were	  suicidal	  at	  one	  point	  of	  their	  lives	  (McKee,	  2013).	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   Recent	  studies	  have	  shown	  a	  central	  mechanism	  responsible	  for	  the	  pathogenesis	  of	  hyperphosphorylated	  tau	  proteins	  (Blaylock	  et	  al.,	  2011).	  	  When	  a	  person	  sustains	  an	  MTBI,	  there	  is	  a	  massive	  release	  of	  glutamate	  and	  aspartate	  from	  both	  astrocytes	  and	  microglia	  cells	  and	  delayed	  uptake	  of	  the	  neurotransmitters,	  which	  causes	  over	  stimulation	  glutamate	  receptors	  and	  subsequently,	  an	  influx	  of	  calcium	  through	  the	  cell	  membrane	  (Maroon	  et	  al.,	  2014).	  	  This	  process	  leads	  to	  excitotoxicity	  and	  eventually	  to	  neuronal	  toxicity	  and	  apoptosis,	  cell	  death	  (Maroon	  et	  al.,	  2012).	  	  The	  microglia	  that	  were	  primed	  by	  the	  initial	  head	  trauma	  release	  a	  variety	  of	  immune	  factors	  including	  prostaglandins,	  pro-­‐inflammatory	  cytokines	  and	  additional	  glutamate,	  aspartate,	  and	  quinolinic	  acid	  (Maroon	  et	  al.,	  2014).	  	  	  Normally,	  the	  pro-­‐inflammatory	  cytokines	  create	  a	  healing	  response	  in	  the	  brain,	  but	  through	  additional	  head	  trauma,	  the	  microglia	  remain	  active,	  produce	  more	  cytokines,	  glutamate,	  aspartate,	  and	  quinolinic	  acid,	  and	  a	  chronic	  neuroinflammatory	  state	  occurs	  (Maroon	  et	  al.,	  2014).	  	  Cytokines	  and	  excitotoxins	  like	  glutamate	  and	  quinolinic	  acid	  increase	  the	  levels	  of	  reactive	  oxygen	  and	  reactive	  nitrogen	  intermediates,	  which	  interfere	  with	  glutamate	  clearance	  causing	  an	  exponential	  increase	  in	  immunoexcitotoxicity	  (Blaylock	  et	  al.,	  2011).	  	  High	  levels	  of	  glutamate	  and	  quinolinic	  acid	  significantly	  increase	  the	  deposition	  of	  hyperphosphorylated	  tau	  protein	  resulting	  in	  neurofibrillary	  accumulation	  in	  the	  brain	  (Blaylock	  et	  al.,	  2011).	  	  The	  reaction	  between	  pro-­‐inflammatory	  cytokines	  and	  glutamate	  receptors	  causes	  a	  hyperreactive	  response	  and	  worsens	  neurodegeneration	  mostly	  in	  the	  frontal	  lobes,	  hippocampus,	  and	  parietal	  lobes	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causing	  immunoexcitotoxicity	  (Blaylock	  et	  al.,	  2011).	  	  Figure	  1	  shows	  immunoexcitotoxicity	  as	  the	  underlying	  mechanism	  behind	  the	  development	  of	  CTE	  (Maroon	  et	  al.,	  2014).	  	  	  
Figure	  1	  Microglial	  Activation	  Leading	  to	  Immunoexcitotoxicity	  	  
	  (Maroon	  et	  al.,	  2012)	  	  	   Multiple	  studies	  have	  found	  a	  genetic	  risk	  factor	  for	  the	  formation	  of	  CTE	  via	  genotyping	  confirmed	  cases	  of	  CTE	  postmortem	  (McKee	  et	  al.,	  2009).	  	  McKee	  and	  colleagues	  performed	  a	  case	  study	  of	  10	  cases	  of	  CTE	  in	  contact	  sport	  athletes	  and	  found	  an	  association	  of	  CTE	  with	  the	  Apolipoprotein	  E4	  gene	  (Mckee	  et	  al.,	  2009).	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Five	  of	  the	  ten	  cases	  of	  CTE	  carried	  at	  least	  one	  Apolipoprotein	  E4	  allele	  and	  one	  was	  homozygous	  for	  Apolipoprotein	  E4	  (McKee	  et	  al.,	  2009).	  	  The	  percentage	  of	  Apolipoprotein	  E4	  carriers	  in	  the	  general	  population	  is	  15%,	  which	  suggests	  inheritance	  of	  the	  allele	  may	  be	  a	  risk	  factor	  for	  the	  development	  of	  CTE	  (McKee	  et	  al.,	  2009).	  	  Studies	  have	  also	  shown	  stronger	  evidence	  that	  the	  traumatic	  effects	  of	  MTBI	  are	  more	  severe	  in	  individuals	  that	  are	  Apolipoprotein	  E4	  positive	  (McKee	  et	  al.,	  2009).	  	  The	  Apolipoprotein	  E4	  genotype	  is	  associated	  with	  clinically	  detectable	  neurological	  deficits	  in	  contact	  sport	  athletes	  (Geddes,	  1999).	  	  Apolipoprotein	  E4	  also	  confers	  genetic	  susceptibility	  to	  the	  formation	  of	  neurofibrillary	  tangles	  in	  the	  brain	  in	  the	  absence	  of	  AB	  amyloid	  plaques,	  suggesting	  a	  strong	  correlation	  with	  vessels	  (Geddes,	  1999).	  	  A	  study	  with	  mice	  showed	  greater	  mortality	  from	  TBI	  in	  Apolipoprotein	  E4	  positive	  mice	  compared	  to	  those	  that	  did	  not	  express	  the	  gene	  (McKee	  et	  al.,	  2009).	  	  	  
Current Research Progressing the Study of CTE  	   With	  the	  growing	  knowledge	  of	  MTBI	  and	  it’s	  link	  to	  CTE,	  recent	  research	  has	  focused	  on	  in	  vivo	  studies	  of	  changes	  in	  brain	  chemistry	  in	  order	  to	  potentially	  diagnose	  CTE	  at	  an	  earlier	  stage	  (Johnson	  et	  al.,	  2015).	  	  As	  discussed,	  diffuse	  axonal	  injury	  is	  a	  common	  feature	  of	  repetitive	  MTBI	  and	  is	  a	  predominant	  pathology	  of	  CTE	  (Johnson	  et	  al.,	  2015).	  	  In	  a	  recent	  study,	  a	  proteolytic	  fragment	  of	  alpha-­‐II	  spectrin,	  SNTF,	  was	  detected	  in	  serum	  following	  MTBI	  and	  was	  correlated	  to	  poor	  clinical	  outcome	  with	  a	  possible	  link	  to	  development	  of	  CTE	  (Johnson	  et	  al.,	  2015).	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Johnson	  and	  colleagues	  used	  immunohistochemistry	  to	  examine	  for	  SNTF	  in	  brain	  serum	  in	  patients	  post-­‐mortem	  following	  both	  severe	  TBI	  and	  MTBI	  (Johnson	  et	  al.,	  2015).	  	  Immunohistochemistry	  revealed	  an	  SNTF	  subpopulation	  of	  degenerating	  axons	  undetected	  by	  previous	  studies	  (Johnson	  et	  al.,	  2015).	  	  The	  data	  shows	  that	  multiple	  pathological	  axonal	  phenotypes	  exist	  post	  MTBI	  and	  there	  is	  a	  more	  comprehensive	  approach	  to	  the	  neuropathological	  assessment	  of	  axonal	  injury	  and	  tau	  pathology	  in	  the	  brains	  of	  those	  who	  suffered	  from	  repetitive	  MTBI	  (Johnson	  et	  al.,	  2015).	  	  With	  the	  new	  development	  of	  SNTF	  as	  a	  clinically	  relevant	  biomarker	  of	  axonal	  injury	  and	  the	  discovery	  of	  multiple	  pathological	  features	  of	  axonal	  injury,	  future	  studies	  will	  be	  able	  to	  focus	  on	  the	  prevalence	  of	  SNTF	  after	  MTBI	  and	  its	  correlation	  to	  CTE	  (Johnson	  et	  al.,	  2015).	  	  	  	   One	  of	  the	  most	  innovate	  recent	  studies	  identifies	  changes	  in	  the	  neurochemistry	  of	  contact	  sport	  athletes	  who	  suffered	  repetitive	  MTBI	  with	  the	  goal	  to	  assess	  risk	  for	  the	  development	  of	  CTE	  and	  to	  potentially	  diagnose	  CTE	  in	  vivo	  as	  shown	  in	  Figure	  2	  (Lin	  et	  al.,	  2015).	  	  The	  study	  used	  a	  relatively	  new	  technology,	  in	  
vivo	  Localized	  Correlated	  Spectroscopy	  (L-­‐COSY)	  to	  identify	  differing	  neurochemicals	  in	  the	  brains	  of	  professional	  athletes	  who	  suffered	  repetitive	  MTBI	  versus	  a	  control	  group	  (Lin	  et	  al.,	  2015).	  	  L-­‐COSY	  uses	  a	  simple	  three-­‐pulse	  sequence,	  which	  provides	  a	  chemical	  specificity	  not	  available	  to	  conventional	  one-­‐dimensional	  magnetic	  resonance	  spectroscopy	  (Lin	  et	  al.,	  2015).	  	  The	  cohort	  involved	  profession	  athletes	  involved	  with	  football,	  wrestling,	  and	  baseball	  that	  ranged	  in	  cognitive	  and	  neuropsychiatric	  symptom	  severity,	  but	  had	  been	  playing	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their	  respective	  sport	  for	  at	  least	  10	  years	  (Lin	  et	  al.,	  2015).	  	  Brains	  of	  those	  who	  suffered	  repetitive	  MTBI	  showed	  a	  significant	  increase	  in	  neurochemicals	  compared	  to	  the	  control	  group	  of	  glutamine/glutamate	  (35%	  greater),	  choline	  (65%	  greater),	  threonine	  (60%	  greater),	  and	  phenylalanine	  (Lin	  et	  al.,	  2015).	  	  It	  was	  previously	  known	  that	  there	  was	  a	  large	  increase	  in	  glutamate	  in	  those	  who	  suffer	  repetitive	  MTBI	  and	  that	  was	  a	  strong	  link	  to	  the	  development	  of	  CTE,	  but	  the	  increase	  in	  choline,	  threonine,	  and	  phenylalanine	  are	  a	  new	  significant	  findings	  and	  may	  lead	  to	  early	  “in	  life”	  detection	  of	  CTE	  (Lin	  et	  al.,	  2015).	  	  	  
Figure	  2	  Metabolite	  Difference	  in	  Professional	  Athletes	  Versus	  Control	  Group	  
(Lin	  et	  al.,	  2015)	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Prevention and Treatment of MTBI 	   The	  best	  and	  most	  effective	  way	  to	  decrease	  the	  incidence	  of	  MTBI,	  and	  thus	  CTE,	  is	  to	  decrease	  exposure	  to	  head	  trauma	  (McKee	  et	  al.,	  2009).	  	  In	  contact	  sports,	  the	  best	  way	  to	  decrease	  exposure	  to	  trauma	  is	  by	  penalizing	  intentional	  hits	  to	  the	  head,	  which	  is	  currently	  happening	  in	  sports	  like	  hockey	  and	  football	  (McKee	  et	  al.,	  2009).	  	  The	  National	  Football	  League	  (NFL)	  began	  to	  penalize	  illegal	  blows	  to	  the	  head,	  hitting	  defenseless	  players,	  head-­‐down	  tackling,	  hands	  to	  the	  face,	  as	  well	  as	  blind	  side	  hits	  in	  order	  to	  protect	  the	  athletes	  (Maroon	  et	  al.,	  2014).	  	  In	  addition	  to	  a	  penalty	  on	  the	  field,	  the	  NFL	  has	  begun	  to	  fine	  players	  as	  well	  as	  enforce	  suspensions	  for	  broken	  rules	  (Maroon	  et	  al.,	  2014).	  	  The	  newer	  rules	  have	  significantly	  decreased	  the	  number	  of	  concussions	  (Maroon	  et	  al.,	  2014).	  The	  NFL	  has	  also	  created	  a	  more	  strict	  care	  and	  management	  system	  for	  MTBI	  (Maroon	  et	  al.,	  2014).	  	  With	  any	  blow	  to	  the	  head	  and	  immediate	  symptoms	  including	  dizziness	  and	  headache,	  the	  players	  are	  removed	  from	  the	  game	  by	  either	  the	  referee	  or	  the	  training	  staff	  and	  must	  go	  through	  clinical	  evaluation,	  ImPACT	  testing,	  and	  VOMS	  testing	  on	  the	  sideline	  (Maroon	  et	  al.,	  2014).	  	  By	  having	  improved	  guidelines	  for	  the	  handling	  of	  on	  the	  field	  MTBI,	  it	  has	  decreased	  the	  risk	  for	  immediate	  MTBI	  and	  further	  brain	  damage	  (Maroon	  et	  al.,	  2014).	  	  	  In	  contact	  sports,	  including	  American	  football,	  impact	  occurs	  on	  every	  play.	  	  Next	  to	  impact	  avoidance,	  football	  helmets	  are	  the	  most	  important	  factor	  protecting	  a	  player	  from	  MTBI	  (Pellman	  et	  al.,	  2006).	  	  In	  the	  early	  1970’s	  the	  National	  Football	  League	  began	  to	  develop	  newer	  helmets,	  which	  significantly	  decreased	  the	  number	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of	  head	  injuries	  by	  1980	  (Pellman	  et	  al.,	  2006).	  	  The	  NFL’s	  Committee	  on	  Mild	  Traumatic	  Brain	  Injury	  conducted	  further	  injury	  on	  the	  effectiveness	  of	  football	  helmets	  in	  order	  to	  discover	  faults	  in	  the	  design	  and	  improve	  upon	  the	  helmet	  (Pellman	  et	  al.,	  2006).	  	  The	  committee	  used	  two	  high-­‐speed	  videos	  recording	  head	  kinetics	  in	  order	  to	  study	  helmet	  design	  and	  to	  reconstruct	  an	  improved	  version	  (Pellman	  et	  al.,	  2006).	  	  Via	  the	  kinematic	  studies	  it	  was	  found	  that	  MTBI	  in	  professional	  football	  involves	  a	  mean	  impact	  velocity	  of	  20.8	  miles	  per	  hour	  and	  a	  head	  velocity	  change	  of	  16.1	  miles	  per	  hour,	  which	  are	  exceptionally	  high	  velocities	  and	  accelerations	  (Pellman	  et	  al.,	  2006).	  	  	  	   The	  Committee	  on	  Mild	  Traumatic	  Brain	  Injury	  performed	  studies	  to	  better	  understand	  the	  biomechanics	  of	  helmet	  impact,	  including	  location	  and	  direction	  of	  trauma	  (Pellman	  et	  al.,	  2006).	  	  The	  study	  showed	  helmet	  to	  helmet	  and	  helmet	  to	  ground	  impacts	  of	  both	  the	  striking	  player	  and	  the	  struck	  player	  (Pellman	  et	  al.,	  2006).	  	  The	  majority	  of	  the	  hits	  taken	  by	  the	  struck	  player	  were	  on	  the	  side	  of	  the	  helmet	  and	  in	  the	  facemask	  area	  on	  the	  front,	  which	  demonstrated	  the	  importance	  of	  the	  presence	  of	  a	  facemask	  on	  all	  helmets	  (Pellman	  et	  al.,	  2006).	  	  The	  majority	  of	  hits	  to	  the	  head	  of	  the	  striking	  players	  occurred	  at	  the	  crown	  of	  the	  head	  on	  both	  sides,	  which	  proposed	  a	  concern	  for	  tackling	  technique	  in	  football	  players	  (Pellman	  et	  al.,	  2006).	  	  In	  head-­‐down	  tackling,	  where	  the	  player	  lowers	  his	  head	  in	  order	  to	  deliver	  a	  blow	  to	  the	  opponent,	  neck	  injuries	  and	  concussions	  have	  been	  more	  prevalent	  in	  the	  opponent	  (Pellman	  et	  al.,	  2006).	  	  It	  was	  found	  that	  when	  the	  striking	  player	  lowers	  the	  head,	  neck,	  and	  torso,	  the	  player	  is	  able	  to	  deliver	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maximum	  force	  to	  the	  struck	  player,	  whose	  head	  and	  neck	  must	  resist	  the	  impact	  (Pellman	  et	  al.,	  2006).	  	  In	  this	  situation,	  rule	  changes	  that	  penalized	  head-­‐down	  tackling	  in	  football,	  would	  significantly	  decrease	  MTBI	  (Pellman	  et	  al.,	  2006).	  	   The	  NFL	  testing	  techniques	  addressing	  concussion	  provided	  newer	  helmets	  including	  the	  Adams	  USA	  Pro	  Elite,	  Riddell	  Revolution,	  and	  Schutt	  Sport	  Air	  Varsity	  Commander	  and	  DNA	  helmets	  (Pellman	  et	  al.,	  2006).	  	  The	  newer	  helmets	  were	  then	  tested	  to	  determine	  their	  overall	  performance	  versus	  previously	  used	  helmets	  (Pellman	  et	  al.,	  2006).	  	  	  Testing	  revealed	  that	  newer	  football	  helmets	  reduce	  concussion	  risks	  in	  collisions	  in	  the	  range	  of	  ten	  to	  twenty	  percent	  (Pellman	  et	  al.,	  2006).	  	  The	  newer	  helmets	  reduce	  MTBI	  risk	  by	  using	  thicker	  and	  greater	  energy	  absorbing	  material	  on	  the	  side	  and	  back	  of	  the	  helmets,	  as	  well	  as	  around	  the	  ears	  (Pellman	  et	  al.,	  2006).	  	  	  	   A	  study	  specifically	  looked	  at	  concussion	  rates	  and	  recovery	  times	  for	  athletes	  wearing	  newer	  helmet	  technology	  compared	  to	  the	  earlier	  helmet	  designs	  (Collins	  et	  al.,	  2006).	  	  The	  study	  was	  a	  three-­‐year	  cohort	  study	  where	  half	  of	  2,141	  high	  school	  athletes	  wore	  Riddell	  Revolution	  helmets	  and	  the	  remainder	  used	  standard	  helmets	  (Collins	  et	  al.,	  2006).	  	  The	  athletes	  underwent	  ImPACT	  baseline	  studies	  and	  were	  reevaluated	  at	  various	  time	  intervals	  following	  a	  concussion	  (Collins	  et	  al.,	  2006).	  	  As	  seen	  in	  figure	  12,	  changes	  in	  the	  Riddell	  Revolution	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Figure	  3	  Riddell	  Revolution	  Helmet	  Versus	  Traditional	  Football	  Helmet	  	  
	  (Collins	  et	  al.,	  2006)	  	  include	  a	  facemask	  with	  a	  greater	  surface	  area,	  improved	  energy	  absorbing	  material	  to	  the	  back	  and	  sides	  of	  the	  helmet,	  as	  well	  as	  new	  padding	  around	  the	  zygoma	  and	  mandible	  region	  (Collins	  et	  al.,	  2006).	  	  The	  study	  by	  Collins	  and	  his	  colleagues	  provided	  preliminary	  evidence	  that	  new	  helmet	  technology	  might	  substantially	  reduce,	  but	  certainly	  not	  prevent,	  the	  occurrence	  and	  incidence	  of	  MTBI	  in	  high	  school	  football	  players,	  as	  well	  as	  initiate	  a	  trend	  toward	  faster	  recovery	  time	  in	  the	  athletes	  wearing	  the	  newer	  technology	  (Collins	  et	  al.,	  2006).	  	  The	  concussion	  rate	  in	  athletes	  wearing	  the	  Riddell	  Revolution	  was	  5.3	  percent	  compared	  to	  7.6	  percent	  in	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those	  wearing	  traditional	  helmets	  (Collins	  et	  al.,	  2006).	  	  Wearing	  the	  Riddell	  helmet	  created	  an	  approximately	  31	  percent	  decreased	  relative	  risk	  for	  sustaining	  an	  MTBI	  despite	  not	  differing	  from	  mechanism	  of	  injury,	  on-­‐field	  concussion	  markers,	  or	  on-­‐field	  presentation	  of	  symptoms,	  showing	  the	  beneficial	  effects	  in	  reducing	  the	  incidence	  of	  MTBI	  in	  high	  school	  athletes	  (Collins	  et	  al.,	  2006).	  	  	  	   A	  case	  study	  was	  performed	  on	  six	  pediatric	  athletes	  with	  prolonged	  MTBI	  symptoms	  to	  determine	  if	  certain	  physical	  therapy	  approaches	  help	  speed	  up	  recovery	  and	  eliminate	  symptoms	  (Hugentobler	  et	  al.,	  2015).	  	  Patients	  were	  treated	  for	  7	  sessions	  over	  10	  weeks	  and	  received	  a	  combination	  of	  cardiovascular,	  musculoskeletal,	  postural	  control,	  and	  vestibular/oculomotor	  interventions	  (Hugentobler	  et	  al.,	  2015).	  	  The	  goal	  of	  the	  cardiovascular	  sessions	  was	  to	  progressively	  increase	  endurance	  and	  activity	  tolerance	  with	  minimal	  to	  no	  symptom	  exacerbation	  (Hugentobler	  et	  al.,	  2015).	  	  The	  goals	  of	  the	  musculoskeletal	  sessions	  were	  to	  improve	  range	  of	  motion,	  muscle	  activation	  and	  condition,	  and	  improve	  appropriate	  postural	  musculature	  (Hugentoblet	  et	  al.,	  2015).	  	  The	  goals	  of	  postural	  control	  were	  to	  address	  deficits	  in	  balance,	  stability,	  proprioception,	  and	  neuromuscular	  control	  (Hugentobler	  et	  al.,	  2015).	  	  The	  goal	  of	  the	  vestibular/oculomotor	  sessions	  was	  to	  eliminate	  symptom	  exacerbation	  with	  concurrent	  head	  and	  eye	  movement	  (Hugentobler	  et	  al.,	  2015).	  	  All	  of	  the	  athletes	  showed	  improvement	  in	  the	  post-­‐concussion	  symptom	  scale	  after	  physical	  therapy	  interventions	  with	  four	  of	  the	  six	  athletes	  returning	  to	  their	  pre-­‐injury	  level	  of	  activity,	  while	  two	  returned	  to	  a	  modified	  activity	  level	  upon	  completion	  of	  physical	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therapy	  (Hugentobler	  et	  al.,	  2015).	  	  The	  greatest	  improvements	  were	  shown	  following	  postural	  control	  and	  vestibular/oculomotor	  sessions	  and	  the	  study	  suggests	  that	  greater	  focus	  should	  be	  placed	  on	  those	  therapies	  in	  future	  studies	  and	  treatment	  (Hugentobler	  et	  al.,	  2015).	  	   A	  recent	  study	  has	  focused	  on	  the	  pharmaceutical	  Amantadine,	  and	  its	  effectiveness	  in	  the	  treatment	  of	  symptoms	  and	  neurocognitive	  performance	  of	  athletes	  suffering	  from	  MTBI	  (Reddy	  et	  al.,	  2013).	  	  Amantadine	  is	  a	  dopaminergic	  agent,	  traditionally	  approved	  for	  Parkinson’s	  disease,	  that	  presynaptically	  forces	  the	  release	  of	  dopamine	  and	  inhibits	  reuptake,	  thus	  increasing	  the	  concentration	  of	  dopamine	  in	  the	  synaptic	  cleft	  (Reddy	  et	  al.,	  2013).	  	  In	  the	  study,	  a	  group	  of	  patients	  were	  treated	  with	  100	  mg	  Amantadine	  twice	  daily	  and	  compared	  to	  a	  control	  group	  who	  were	  not	  treated	  via	  measurement	  based	  on	  ImPACT	  testing	  (Reddy	  et	  al.,	  2013).	  	  The	  study	  showed	  that	  treatment	  with	  Amantadine	  resulted	  in	  a	  significant	  decrease	  in	  reported	  symptoms	  as	  well	  as	  improvements	  in	  verbal	  memory	  and	  reaction	  time	  compared	  to	  the	  control	  cohort,	  especially	  in	  patients	  that	  had	  their	  symptoms	  for	  greater	  than	  three	  weeks	  following	  diagnosis	  of	  MTBI	  (Reddy	  et	  al.,	  2013).	  	  	  	   With	  many	  recent	  studies	  linking	  MTBI	  to	  CTE	  focusing	  on	  a	  progressive	  immunoexcitotoxicity	  including	  cytokines	  and	  neurotransmitters	  like	  glutamate,	  aspartate,	  and	  quinolinic	  acid	  creating	  a	  neuro-­‐inflammation	  process,	  the	  recent	  focus	  on	  treatment	  of	  MTBI	  has	  been	  with	  anti-­‐inflammatory	  agents	  (Maroon	  et	  al.,	  2012).	  	  The	  approach	  for	  many	  years	  has	  been	  to	  treat	  MTBI	  via	  pharmacological	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management	  centered	  on	  symptom	  management	  (Maroon	  et	  al.,	  2012).	  	  Pharmacological	  treatments	  have	  caused	  side	  effects	  that	  may	  exacerbate	  other	  symptoms	  present	  in	  MTBI	  patients	  (Maroon	  et	  al.,	  2012).	  	  Pharmacological	  agents	  currently	  prescribed	  for	  MTBI	  symptoms	  include	  stimulants	  like	  D-­‐amphetamine	  (Adderall)	  and	  Methylphenidate	  (Ritalin),	  which	  traditionally	  are	  approved	  for	  ADHD	  and	  narcolepsy	  and	  may	  cause	  increased	  anxiety,	  headaches,	  and	  dizziness	  (Maroon	  et	  al.,	  2012).	  	  Others	  include	  Bupropion	  (Wellbutrin),	  Fluoxetine	  (Prozac),	  Escitalopram	  (Lexapro),	  and	  Amitiptyline	  (Elavil),	  which	  are	  traditionally	  approved	  for	  depression	  and	  panic	  attacks	  and	  may	  cause	  increased	  dizziness,	  anxiety,	  and	  impaired	  concentration/memory	  among	  other	  side	  effects	  (Maroon	  et	  al.,	  2012).	  	  Side	  effects	  only	  occur	  in	  a	  certain	  percentage	  of	  patients,	  but	  tend	  to	  exacerbate	  symptoms	  present	  in	  most	  patients	  suffering	  from	  MTBI	  (Maroon	  et	  al.,	  2012).	  	  	  	   With	  improved	  evidence	  of	  increased	  glutamate,	  aspartate,	  quinolinic	  acid,	  and	  other	  neurotransmitters	  in	  the	  brains	  of	  those	  suffering	  from	  MTBI,	  more	  of	  the	  focus	  should	  be	  put	  on	  natural	  anti-­‐inflammatory	  agents	  that	  are	  able	  to	  counter	  the	  immunoexcitotoxicity	  (Maroon	  et	  al.,	  2012).	  	  Natural	  anti-­‐inflammatory	  agents	  would	  reduce	  inflammation	  with	  far	  fewer	  side	  effects	  (Maroon	  et	  al.,	  2012).	  	  Agents	  such	  as	  omega-­‐3	  essential	  fatty	  acids,	  vitamin	  D3,	  curcumin,	  resveratrol,	  and	  magnesium	  have	  all	  been	  shown	  to	  clinically	  reduce	  inflammation,	  reduce	  microglial	  activation,	  and	  affect	  excitotoxic	  cells	  signaling	  processes	  (Maroon	  et	  al.,	  2012).	  	  Research	  has	  shown	  that	  omega-­‐3	  essential	  fatty	  acids	  reduce	  CTE’s	  mechanisms	  of	  immunoexcitotoxicity	  and	  microglia	  activation	  through	  the	  major	  components	  of	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 Trauma is evident in contact sports including football, boxing, and hockey, and 
despite changes in equipment, MTBI still occur although at a decreased quantity 
(Gardner et al., 2015).  Multiple studies have noted MTBI as the single greatest risk 
factor for the development of CTE and repetitive MTBI only escalates that development 
(Azad et al., 2015).  Although the prevalence of MTBI necessary to develop CTE is 
unknown, repetitive MTBI is clearly linked pathologically to the unique pattern of 
hyperphosphorylated tau neurofibrillary and astrocytic tangles in the brain of individuals 
suffering from CTE (Azad et al., 2015).  Symptomatically, repetitive MTBI is linked to 
progressive deterioration of cognitive functioning, paranoid ideations, exaggerated 
responses to life stressors, mood fluctuations, major depression, alcohol and drug abuse, 
violent behavior and tendencies, and suicides and parasuicides (Omalu, 2010).  Current 
research, including SNFT immunostaining and L-COSY, has expanded on the 
neuropathology of CTE by better describing biomarkers of axonal injury and identifying 
specific changes in neurochemistry of the brains of those suffering from CTE (Johnson et 
al., 2015, Lin et al., 2015).  The current research serves as a platform for future research 
to focus on the in vivo diagnosis of CTE in order to improve prevention and treatment of 
the disease (Lin et al., 2015).   
 Dr. Bennet Omalu, the first to publish findings of CTE in American football 
players, performed a case study on a deceased, former NFL player to further correlate 
repetitive MTBI and the development of CTE (Omalu, 2006).  A complete autopsy was 
accompanied by a comprehensive neuropathological examination as well as a 
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psychological autopsy on the next-of-kin and wife of the deceased NFL player (Omalu, 
2006).  The former NFL player, who had a 14 year career, had reported to his wife that he 
had sustained repeated mild concussions of the head on numerous occasions during his 
NFL career (Omalu, 2006).  During his childhood and amateur and professional football 
career, his wife and family did not observe any obvious psychosocial or behavioral 
abnormalities, but within a few years of his retirement from professional football, his 
wife reported that he became increasingly quiet and was excessively afraid and fearful, 
with paranoid tendencies (Omalu, 2006).  He was very reclusive and distanced himself 
from others including his family and friends, often locking himself inside the house for 
days at a time (Omalu, 2006).  He was described as having extreme highs and lows and 
became incapable of handling complex rational thoughts and matters of daily living 
(Omalu, 2006).  He first attempted suicide by ingesting rat poison and cold medications, 
and was diagnosed with adjustment disorder with depressed mood after that first attempt 
by physicians (Omalu, 2006).  He made several more attempted suicides, was arrested 
multiple times, and was admitted for psychiatric treatment three times (Omalu, 2006).  
He passed away a few weeks after his last discharge from the hospital hours after being 
found lying on a couch in an altered mental status (Omalu, 2006).  It was confirmed that 
he died of a suicide attempted by ingesting ethylene glycol (Omalu, 2006).  Upon 
autopsy, his brain was found to have widespread neuronal and neuropil accumulation of 
cytoskeletal protein to form neurofibrillary tangles, (Omalu, 2006).  The major 
components of the neurfibrillary tangles were hyperphosphorylated tau protein (Omalu, 
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2006).  The immunohistochemical findings along with the symptoms provided by family 
confirmed the diagnosis of CTE for the former NFL player of 14 years (Omalu, 2006).   
 Dr. Omalu along with many others have confirmed CTE in many other 
professional football players, boxers, hockey players, and soccer players (Gardner et al., 
2015).  A recent case study of a hall of fame NFL player, Junior Seau, who was 
confirmed to have suffered from CTE, has sparked greater interest and concern of MTBI 
and it’s link to CTE and has thus propagated coverage in the media (Azad et al., 2015).  
Seau’s case is very similar to that performed by Dr. Omalu (Azad et al., 2015).  Seau had 
a 20-year career in the NFL as a linebacker and had multiple confirmed concussions 
throughout his career (Azad et al., 2015).  During the latter stages of his career and 
increasingly after retirement Seau complained of headaches, dizziness, and insomnia 
(Azad et al., 2015).  His family and friends reported surprising behavioral changes 
including withdrawal, alcohol abuse, increased aggression and violence, reckless 
financial decisions, and gambling (Azad et al., 2015).  Seau was found dead just two 
years after his retirement from the NFL from a self-inflicted gunshot wound to the chest 
(Azad et al., 2015).  Autopsy of Seau’s brain revealed “multi-focal tauopathy consistent 
with a diagnosis of chronic traumatic encephalopathy” (Azad et al., 2015).  Public 
awareness of CTE was quickly increased after the diagnosis in a very high-profile NFL 
player whose cognitive function was altered enough to commit suicide (Azad et al., 
2015).   
 A study was performed to look the prevalence and risk of concussion by position 
in the NFL shown in Table 10 (Pellman et al., 2006).  It was hypothesized that positions 
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that deliver or absorb the most trauma during the game will have the highest incidence 
and that the positions that involve higher impact velocities at collision will be at greatest 
risk (Pellman et al., 2015).  In lines with the hypothesis, positions such as defensive  
 
Table 10 Incidence of MTBI Based on Player Position in NFL Games 
 
(Pellman et al., 2006).  
secondary and kick unit, which deliver significant trauma throughout a game have the 
highest incidence in MTBI (Pellman et al., 2006).  Positions like quarterback and wide 
receiver, which absorb hits at high impact velocity, are at the greatest risk for MTBI 
(Pellman et al., 2006).  Linebacker, which Junior Seau played, is a position that delivers a 
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significant amount of hits throughout at game and saw a 6.6% incidence in MTBI and 
was at a 0.45 risk for MTBI (Pellman et al., 2006).   
 The link of MTBI to CTE is disturbing due to the symptoms described in 
individuals at such a young age (Maroon et al., 2014).  Some have argued for the 
abandonment of sports such as American football, but others continue to recognize the 
valuable benefits gained from team participation in contact sports (Maroon et al., 2014).  
Characteristics such as perseverance in times of adversity, leadership, tenacity, and 
teamwork develop from team participation in contact sports and are greatly beneficial to 
young individuals, especially if they are able to further the develop the characteristics 
throughout life (Maroon et al., 2014).  Great changes have been made to protect 
American football and the individuals playing the sport including rule changes, 
improving protective gear and helmets, and concussion regulations, but more research 
needs to be conducted to continue the process (Maroon et al., 2014).  The future focus of 
MTBI research and the link to CTE will be diagnostic tools and imaging tests to allow for 
in vivo diagnosis of CTE, which will create the opportunity for improved prevention and 
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  of	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